RevolKa

Executive Summary

RevolKa is a Japanese biotechnology company leveraging its proprietary aiProtein® platform to engineer high-performance proteins, including antibodies and enzymes, for therapeutic applications in rare diseases. Founded in 2021 and headquartered in Sendai, the company integrates artificial intelligence with directed evolution to dramatically accelerate protein engineering, reducing development timelines from years to months. RevolKa has raised approximately ¥710 million in funding and operates as a platform-stage private company with 10-50 employees. The aiProtein platform uses AI predictions combined with laboratory data to optimize protein properties such as stability, affinity, and specificity, enabling the creation of novel biopharmaceuticals with enhanced efficacy. RevolKa's focus on rare diseases positions it in a high-value niche with significant unmet medical need. The company's core strength lies in its ability to rapidly generate optimized proteins that are difficult to develop using conventional methods. As a young firm in the competitive AI-driven drug discovery space, RevolKa aims to partner with pharmaceutical companies and research institutions to advance its pipeline. The combination of AI and directed evolution is a validated approach, and the company's progress will hinge on successful proof-of-concept studies and strategic collaborations. With a lean team and modest funding, RevolKa represents an early-stage opportunity in computational protein design.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership or licensing deal with a major pharma company40% success
• Q2 2026Publication of preclinical data demonstrating aiProtein platform's superiority60% success
• Q3 2026Series A funding round or grant from Japanese government/innovation agency50% success